Prelude Capital Management’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

Prelude Capital Management’s Portfolio NDRM Stock Details NDRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-91,533	Closed	-$3.56M	–	2013
2017 Q3	$3.56M	Buy	91,533 +90,657	+10,349%	+$3.33M	0.32%	65
2017 Q2	$26K	Buy	+876	New	+$22.7K	﹤0.01%	1205
2017 Q1	–	Sell	-5,283	Closed	-$117K	–	2008
2016 Q4	$117K	Buy	+5,283	New	+$98.8K	0.01%	778

Other funds holding NDRM

VOAM

Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return

OTC

Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

FWM

Focused Wealth Management Newburgh, New York $964M AUM 18.71% 1-Year Est. Return

Prelude Capital Management's NDRM Position: Q4 2017 in Review

Prelude Capital Management sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q4 2017, closing a stake of 91,533 shares — an estimated $3.56M sold.

Prelude Capital Management first reported a position in NDRM in Q4 2016 and held it in 3 quarters. The position peaked at $3.56M in Q3 2017. 5 funds tracked by Wall St. Rank hold NDRM as of Q4 2017.

Prelude Capital Management reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q4 2017 after selling out during the quarter.
Prelude Capital Management sold 91,533 NeuroDerm Ltd. Ordinary Shares shares in Q4 2017, an estimated $3.56M.
Prelude Capital Management first reported a position in NeuroDerm Ltd. Ordinary Shares in Q4 2016 and held it in 3 quarters.
Prelude Capital Management's NeuroDerm Ltd. Ordinary Shares position peaked at $3.56M in Q3 2017.
5 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q4 2017.

Based on Prelude Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.